Deutsche Bank initiated coverage of Ascentage Pharma with a Buy rating and $40 price target. The company two \"de-risked, commercially validated\" mechanisms in olverembatinib and Lisaftoclax, the analyst tells investors in a research note. The firm believes Lisaftoclax is positioned for continued commercial traction in China, which provides immediate access to larger patient volumes.
